Trials / Completed
CompletedNCT01408615
A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Post Marketing Surveillance for General Drug Use to Assess the Safety and Efficacy Profile of ELONVA in Usual Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 472 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This observational study will examine the safety and efficacy profile of Elonva (corifollitropin alfa) when administered in Korean women undergoing controlled ovarian stimulation (COS) in combination with a gonadotropin-releasing hormone (GnRH) antagonist for the development of multiple follicles in an assisted reproductive technology (ART) program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | corifollitropin alfa | 100 or 150 microgram single subcutaneous injection |
Timeline
- Start date
- 2011-09-20
- Primary completion
- 2016-11-18
- Completion
- 2016-11-18
- First posted
- 2011-08-03
- Last updated
- 2022-02-03
Source: ClinicalTrials.gov record NCT01408615. Inclusion in this directory is not an endorsement.